Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 5/2021

01-05-2021 | Care | Original Paper

The Pre-exposure Prophylaxis (PrEP) Care Cascade in People Who Inject Drugs: A Systematic Review

Authors: Colleen B. Mistler, Michael M. Copenhaver, Roman Shrestha

Published in: AIDS and Behavior | Issue 5/2021

Login to get access

Abstract

Injection drug use is a key risk factor for the transmission of HIV. Prevention strategies, such as the use of pre-exposure prophylaxis (PrEP), are effective at reducing the risk of HIV transmission in people who inject drugs (PWID). Following PRISMA guidelines, a literature search was conducted to identify the current state of the PrEP care cascade in PWID. Twenty-three articles were evaluated in this systematic review. A decline in engagement throughout the stages of the PrEP care cascade was found. High awareness and willingness to use PrEP was found, yet PrEP uptake was relatively low (0–3%). There is a lack of research on interventions to increase engagement of PrEP across all levels of the care cascade in PWID. Implications from the interventions that have been published provide insight into practice and public policy on efficacious strategies to reduce HIV incidence in PWID. Our findings suggest that more efforts are needed to identify and screen PWID for PrEP eligibility and to link and maintain them with appropriate PrEP care.
Literature
1.
2.
3.
Kral AH, et al. HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco. J Urban Health. 2005;82(1):i43–50.PubMedPubMedCentral
4.
5.
Volkow ND, Montaner J. The urgency of providing comprehensive and integrated treatment for substance abusers with HIV. Health Aff (Millwood). 2011;30(8):1411–9.
6.
Alpren C, et al. Opioid use fueling HIV transmission in an urban setting: an outbreak of HIV infection among people who inject drugs-massachusetts, 2015-2018. Am J Public Health. 2020;110(1):37–44.PubMedPubMedCentral
7.
Larney S, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health. 2017;5(12):e1208–20.PubMedPubMedCentral
8.
Substance Abuse and Mental Health Services Administration. Medicaid coverage of medication-assisted treatment for alcohol and opioid use disorders and of medication for the reversal of opioid overdose. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2018.
9.
Priest KC, et al. Comparing Canadian and United States opioid agonist therapy policies. Int J Drug Policy. 2019.
10.
The Foundation for AIDS Research. Toward an effective strategy to combat HIV, hepatitis c and the opioid epidemic: recommendations for policy makers. Washington, DC; 2019.
11.
12.
13.
Choopanya K, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.PubMed
14.
15.
Closson EF, et al. Exploring strategies for PrEP adherence and dosing preferences in the context of sexualized recreational drug use among MSM: a qualitative study. AIDS Care. 2018;30(2):191–8.PubMed
16.
Oldenburg CE, et al. Differences in attitudes about HIV pre-exposure prophylaxis use among stimulant versus alcohol using men who have sex with men. AIDS Behav. 2016;20(7):1451–60.PubMedPubMedCentral
17.
Storholm ED, et al. Risk perception, sexual behaviors, and PrEP adherence among substance-using men who have sex with men: a qualitative study. Prev Sci. 2017;18(6):737–47.PubMedPubMedCentral
18.
Wade Taylor S, et al. Optimizing content for pre-exposure prophylaxis (PrEP) counseling for men who have sex with men: perspectives of PrEP users and high-risk PrEP naive men. AIDS Behav. 2014;18(5):871–9.PubMed
19.
Walters SM, et al. Differences in awareness of pre-exposure prophylaxis and post-exposure prophylaxis among groups at-risk for HIV in New York State: New York City and Long Island, NY, 2011-2013. J Acquir Immune Defic Syndr. 2017;75(Suppl 3):S383–91.PubMed
20.
Footer KHA, et al. Exploring new and existing PrEP modalities among female sex workers and women who inject drugs in a U.S. city. AIDS Care. 2019;31(10):1207–13.PubMedPubMedCentral
21.
Peitzmeier SM, et al. Acceptability of microbicidal vaginal rings and oral pre-exposure prophylaxis for HIV prevention among female sex workers in a high-prevalence US city. AIDS Care. 2017;29(11):1453–7.PubMedPubMedCentral
22.
Biello KB, et al. Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs. Harm Reduct J. 2018;15(1):55.PubMedPubMedCentral
23.
Sophus AI, Mitchell JW. A review of approaches used to increase awareness of pre-exposure prophylaxis (PrEP) in the United States. AIDS Behav. 2019;23(7):1749–70PubMed
24.
Stein M, Thurmond P, Bailey G. Willingness to use HIV pre-exposure prophylaxis among opiate users. AIDS Behav. 2014;18(9):1694–700.PubMedPubMedCentral
25.
Khawcharoenporn T, Kendrick S, Smith K. HIV risk perception and preexposure prophylaxis interest among a heterosexual population visiting a sexually transmitted infection clinic. AIDS Patient Care STDS. 2012;26(4):222–33.PubMed
26.
Zhang C, et al. Suboptimal HIV pre-exposure prophylaxis awareness and willingness to use among women who use drugs in the united states: a systematic review and meta-analysis. AIDS Behav. 2019;23(10):2641–53.PubMedPubMedCentral
27.
Allen ST, et al. Barriers and facilitators to PrEP use among people who inject drugs in rural appalachia: a qualitative study. AIDS Behav. 2019.
28.
Bazzi AR, et al. Limited knowledge and mixed interest in pre-exposure prophylaxis for HIV prevention among people who inject drugs. AIDS Patient Care STDS. 2018;32(12):529–37.PubMedPubMedCentral
29.
Roth AM, et al. An exploration of factors impacting preexposure prophylaxis eligibility and access among syringe exchange users. Sex Transm Dis. 2018;45(4):217–21.PubMed
30.
Shrestha R, et al. Developing an integrated, brief biobehavioral HIV prevention intervention for high-risk drug users in treatment: the process and outcome of formative research. Front Immunol. 2017;8:561.PubMedPubMedCentral
31.
Shrestha R, Copenhaver M. Exploring the use of pre-exposure prophylaxis (PrEP) for HIV prevention among high-risk people who use drugs in treatment. Front Public Health. 2018;6:195.PubMedPubMedCentral
32.
Jo Y, et al. Interest in linkage to PrEP among people who inject drugs accessing syringe services; Miami, Florida. PLoS ONE. 2020;15(4):e0231424.PubMedPubMedCentral
33.
Felsher M, et al. An exploration of pre-exposure prophylaxis (PrEP) initiation among women who inject drugs. Arch Sex Behav. 2020.
34.
Walters SM, et al. Awareness of pre-exposure prophylaxis (PrEP) among women who inject drugs in NYC: the importance of networks and syringe exchange programs for HIV prevention. Harm Reduct J. 2017;14(1):40.PubMedPubMedCentral
35.
Kuo I, et al. Willingness to use HIV pre-exposure prophylaxis among community-recruited, older people who inject drugs in Washington, DC. Drug Alcohol Depend. 2016;164:8–13.PubMed
36.
Sherman SG, et al. PrEP awareness, eligibility, and interest among people who inject drugs in Baltimore, Maryland. Drug Alcohol Depend. 2019;195:148–55.PubMed
37.
Metz VE, et al. Racial differences in HIV and HCV risk behaviors, transmission, and prevention knowledge among non-treatment-seeking individuals with opioid use disorder. J Psychoactive Drugs. 2017;49(1):59–68.PubMed
38.
Roth A, et al. Factors associated with awareness of pre-exposure prophylaxis for HIV among persons who inject drugs in philadelphia: national HIV behavioral surveillance, 2015. AIDS Behav. 2019;23(7):1833–40.PubMed
39.
Shrestha R, et al. Willingness to use pre-exposure prophylaxis (PrEP): an empirical test of the information-motivation-behavioral skills (IMB) model among high-risk drug users in treatment. AIDS Behav. 2017;21(5):1299–308.PubMedPubMedCentral
40.
Shrestha R, et al. Integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and reduce HIV risk in people who use drugs: a pilot feasibility study. AIDS Behav. 2018;22(8):2640–9.PubMedPubMedCentral
41.
Shrestha R, et al. Measuring acceptability and preferences for implementation of pre-exposure prophylaxis (PrEP) using conjoint analysis: an application to primary HIV prevention among high risk drug users. AIDS Behav. 2018;22(4):1228–38.PubMedPubMedCentral
42.
Shrestha R, et al. Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment. Drug Alcohol Depend. 2017;173:107–16.PubMedPubMedCentral
43.
Shrestha R, et al. Intent to use preexposure prophylaxis (PrEP), HIV risk behaviors, and self-report neurocognitive symptoms by high-risk drug users: a mediation analysis. J Assoc Nurses AIDS Care. 2017;28(4):612–21.PubMedPubMedCentral
44.
McFarland W, et al. Low PrEP awareness and use among people who inject drugs, San Francisco, 2018. AIDS Behav. 2019.
45.
Gunstad, J., et al. Cluster analysis of data from the brief inventory of neurocognitive impairment (BINI) to develop neuro-cognitive profiles among opioid-dependent patients in drug treatment. Substance Abuse
46.
Earnshaw VA, et al. Intersectionality of internalized HIV stigma and internalized substance use stigma: implications for depressive symptoms. J Health Psychol. 2015;20(8):1083–9.PubMed
47.
48.
Remy L, Enriquez M. Behavioral interventions to enhance PrEP uptake among black men who have sex with men: a review. J Assoc Nurses AIDS Care. 2019;30(2):151–63.PubMedPubMedCentral
49.
50.
Chadwick JJ, et al. Correlates of having never been HIV tested among entrants to substance abuse treatment clinics: empiric findings from real-world New England settings. J Psychoactive Drugs. 2014;46(3):208–14.PubMedPubMedCentral
51.
Metsch LR, et al. Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. Am J Public Health. 2012;102(6):1160–7.PubMedPubMedCentral
52.
53.
Remien RH, et al. Mental health and HIV/AIDS: the need for an integrated response. AIDS (Lond.). 2019;33(9):1411–20.
54.
Dunlop DD, et al. Racial/ethnic differences in rates of depression among preretirement adults. Am J Public Health. 2003;93(11):1945–52.PubMedPubMedCentral
55.
56.
Rich KM, et al. Integrated models of care for individuals with opioid use disorder: how do we prevent HIV and HCV? Curr HIV/AIDS Rep. 2018;15(3):266–75.PubMedPubMedCentral
57.
Molina JM, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4(9):e402–10.PubMed
58.
59.
Kelley CF, et al. Applying a PrEP continuum of care for men who have sex with men in Atlanta, Georgia. Clin Infect Dis. 2015;61(10):1590–7.PubMedPubMedCentral
60.
Wilton J, et al. Use of an HIV-risk screening tool to identify optimal candidates for PrEP scale-up among men who have sex with men in Toronto, Canada: disconnect between objective and subjective HIV risk. J Int AIDS Soc. 2016;19(1):20777.PubMedPubMedCentral
Metadata
Title
The Pre-exposure Prophylaxis (PrEP) Care Cascade in People Who Inject Drugs: A Systematic Review
Authors
Colleen B. Mistler
Michael M. Copenhaver
Roman Shrestha
Publication date
01-05-2021
Publisher
Springer US
Published in
AIDS and Behavior / Issue 5/2021
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-020-02988-x

Other articles of this Issue 5/2021

AIDS and Behavior 5/2021 Go to the issue

Original Paper

Shared Decision Making Between Patients and Healthcare Providers and its Association with Favorable Health Outcomes Among People Living with HIV

Original Paper

COVID-19 Pandemic, Pre-exposure Prophylaxis (PrEP) Care, and HIV/STI Testing Among Patients Receiving Care in Three HIV Epidemic Priority States

Original Paper

Black and Latino Persons Living with HIV Evidence Risk and Resilience in the Context of COVID-19: A Mixed-Methods Study of the Early Phase of the Pandemic

Original Paper

Competence to Consent to Oral and Injectable PrEP Trials Among Adolescent Males Who Have Sex with Males

Original Paper

PrEP Use and PrEP Use Disclosure are Associated with Condom Use During Sex: A Multilevel Analysis of Latino MSM Egocentric Sexual Networks

Original Paper

Examining the Potential of Pre-exposure Prophylaxis (PrEP) for HIV Prevention in a Community Sample of Persons Who Use Stimulants Living in the Southern United States
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits